Injectable GLP-1 has the strongest efficacy data. Oral versions are improving (Foundayo/orforglipron is the closest match), but compounded oral GLP-1 lags behind on outcomes.
Why this comparison matters
Injectable GLP-1 has the strongest efficacy data. Oral versions are improving (Foundayo/orforglipron is the closest match), but compounded oral GLP-1 lags behind on outcomes. This comparison breaks down the practical decision factors that matter to most patients — price, drug type, included services, and operational structure.
Which should you pick?
This is a closer call. Injectable GLP-1 has the strongest efficacy data. Oral versions are improving (Foundayo/orforglipron is the closest match), but compounded oral GLP-1 lags behind on outcomes. Read both full reviews and decide based on your specific priorities:
FAQ
Can I switch between and ?
Yes. Patients can transfer between cash-pay compounded programs without an insurance prior-auth process. Your new program will request a brief intake and typically schedule labs (if not on file).
Is one safer than the other?
Both providers in this comparison meet baseline safety verification. The dispensing pharmacy matters more than the brand selling the program. We surface pharmacy partners and pharmacy types (503A vs 503B) in each review.
Which has better long-term outcomes data?
Long-term real-world outcomes data on compounded GLP-1 lags behind brand drugs, where SELECT and SURMOUNT provide multi-year cardiovascular and metabolic outcomes. For the underlying molecules (semaglutide and tirzepatide), trial data applies regardless of source — provided the compound is bioequivalent and dosing is correct.
This comparison was authored by Eduard Cristea and clinically reviewed by Dr. A. Goher, MD. Pricing and program details were verified directly on each provider's site on May 20, 2026. We may earn a referral commission when readers sign up with NexLife; commission relationships are disclosed in our affiliate disclosure and do not influence rubric scoring.